(Total Views: 634)
Posted On: 10/01/2019 12:17:22 AM
Post# of 72447
Leo said that he will provide more clarity in the coming weeks.
“A new direction, a new understanding of what’s going on, actually growing the company, not shrinking it.”
Leo's riddle is still mainly unanswered. I did not see any hints in the 10 K, but the Locust Walk PR did have a few statement which points to a more aggressive plan to develop partnerships. I expect more news in the upcoming months.
"...we continue to diligently work toward completing other transactions that would unlock additional shareholder value. As such, we are thrilled to engage Locust Walk—with their proven track record and global footprint.”
“We are very selective in deciding which companies to work with,” said Chris Ehrlich, Managing Director and Global Head of Biopharma at Locust Walk. “We look forward to working with Innovation Pharmaceuticals to help them determine the market potential and the best path forward to create value.”
http://www.ipharminc.com/press-release/2019/9...ction-firm
From the Locust Walk web site:
" October 7, 2010: SGI and JCVI announce formation of new company, SGVI, to develop next generation vaccines
SGVI announces three-year collaboration with Novartis on the development of influenza vaccines using synthetic genomics technology. The agreement, supported by an award from the U.S. Biomedical Advanced Research and Development Authority (BARDA), could ultimately lead to a more effective response to seasonal and pandemic flu outbreaks.
https://www.locustwalk.com/our-engagements/sy...-novartis/
My guess is IPIX has several suitors, domestic and international, who are proposing a variety of offers leading IPIX to hire a third party to structure the best deal and facilitate the closing of a deal. A deal which almost certainly will include Brilacidin for Inflammatory Bowel disease.
From the 9/10/2019 PR
Arthur P. Bertolino, MD, PhD, MBA, President and Chief Medical Officer at Innovation Pharmaceuticalsstated,"If oral Brilacidin performs in UC like we believe it can, we should find ourselves in a strong negotiating position toward securing additional licensing agreements in a market that runs into the tens of billions of dollars.”
http://www.ipharminc.com/press-release/2019/9...arter-2019
All IMO,Farrell
“A new direction, a new understanding of what’s going on, actually growing the company, not shrinking it.”
Leo's riddle is still mainly unanswered. I did not see any hints in the 10 K, but the Locust Walk PR did have a few statement which points to a more aggressive plan to develop partnerships. I expect more news in the upcoming months.
"...we continue to diligently work toward completing other transactions that would unlock additional shareholder value. As such, we are thrilled to engage Locust Walk—with their proven track record and global footprint.”
“We are very selective in deciding which companies to work with,” said Chris Ehrlich, Managing Director and Global Head of Biopharma at Locust Walk. “We look forward to working with Innovation Pharmaceuticals to help them determine the market potential and the best path forward to create value.”
http://www.ipharminc.com/press-release/2019/9...ction-firm
From the Locust Walk web site:
" October 7, 2010: SGI and JCVI announce formation of new company, SGVI, to develop next generation vaccines
SGVI announces three-year collaboration with Novartis on the development of influenza vaccines using synthetic genomics technology. The agreement, supported by an award from the U.S. Biomedical Advanced Research and Development Authority (BARDA), could ultimately lead to a more effective response to seasonal and pandemic flu outbreaks.
https://www.locustwalk.com/our-engagements/sy...-novartis/
My guess is IPIX has several suitors, domestic and international, who are proposing a variety of offers leading IPIX to hire a third party to structure the best deal and facilitate the closing of a deal. A deal which almost certainly will include Brilacidin for Inflammatory Bowel disease.
From the 9/10/2019 PR
Arthur P. Bertolino, MD, PhD, MBA, President and Chief Medical Officer at Innovation Pharmaceuticalsstated,"If oral Brilacidin performs in UC like we believe it can, we should find ourselves in a strong negotiating position toward securing additional licensing agreements in a market that runs into the tens of billions of dollars.”
http://www.ipharminc.com/press-release/2019/9...arter-2019
All IMO,Farrell
(9)
(0)
